Literature DB >> 11259522

Unifying perspectives of the mechanisms underlying the development of tolerance and physical dependence to opioids.

D A Taylor1, W W Fleming.   

Abstract

The cellular basis of tolerance to, and dependence upon, many types of drugs, including opioids, has long defied identification. Tolerance to opioids cannot be explained solely on the basis of modification of opioid receptors or altered metabolism or disposition of the opioid. The development of tolerance following chronic exposure to opioids presents at least three different types of change in cellular responsiveness, each of which has been suggested to represent some type of adaptive modification in cellular responsiveness. These different forms of tolerance are distinguishable on the basis of their time course and whether or not the tolerance is specific for opioid receptor agonists (homologous) or extends to agonists of other systems (heterologous). The adaptive modulation of responsiveness via regulation of cellular proteins has been proposed to be the basis for both longer-term forms of tolerance. The divergent signaling pathways activated by G-protein-coupled receptors like the mu-opioid receptor provide multiple downstream targets for both short- and long-term regulation of cell function that is associated with the development of tolerance and/or dependence. Since the magnitude of receptor activation is an important determinant of the degree to which various signaling pathways are activated, the expressed characteristics of tolerance and/or dependence may be functionally related to which of these diverse pathways are stimulated to the greatest degree. Thus, the possibility that different signaling events are activated either sequentially or concurrently offers the possibility to explain the interaction between these different forms of tolerance and/or dependence.

Mesh:

Substances:

Year:  2001        PMID: 11259522

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  30 in total

1.  Spinal CX3CL1/CX3CR1 May Not Directly Participate in the Development of Morphine Tolerance in Rats.

Authors:  Yawen Peng; Genhua Guo; Bin Shu; Daiqiang Liu; Peng Su; Xuming Zhang; Feng Gao
Journal:  Neurochem Res       Date:  2017-08-03       Impact factor: 3.996

2.  Modulatory role of the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine (ADMA), in morphine tolerance and dependence in mice.

Authors:  Ozgur Gunduz; Cetin Hakan Karadag; Ahmet Ulugol
Journal:  J Neural Transm (Vienna)       Date:  2010-07-27       Impact factor: 3.575

3.  Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective.

Authors:  Emily O Dumas; Gary M Pollack
Journal:  AAPS J       Date:  2008-11-07       Impact factor: 4.009

4.  Tolerance to WIN55,212-2 is delayed in desensitization-resistant S426A/S430A mice.

Authors:  Caitlin M Nealon; Angela N Henderson-Redmond; David E Hale; Daniel J Morgan
Journal:  Neuropharmacology       Date:  2019-01-08       Impact factor: 5.250

5.  CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.

Authors:  Liting Deng; Benjamin L Cornett; Ken Mackie; Andrea G Hohmann
Journal:  Mol Pharmacol       Date:  2015-04-22       Impact factor: 4.436

6.  Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series.

Authors:  David J Daniels; Natalie R Lenard; Chris L Etienne; Ping-Yee Law; Sandra C Roerig; Philip S Portoghese
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

7.  Extracellular signal-regulated kinase (ERK) inhibition does not prevent the development or expression of tolerance to and dependence on morphine in the mouse.

Authors:  Lionel Moulédous; Miguel F Díaz; Howard B Gutstein
Journal:  Pharmacol Biochem Behav       Date:  2007-07-18       Impact factor: 3.533

8.  NADPH-oxidase 2 activation promotes opioid-induced antinociceptive tolerance in mice.

Authors:  T Doyle; E Esposito; L Bryant; S Cuzzocrea; D Salvemini
Journal:  Neuroscience       Date:  2013-02-27       Impact factor: 3.590

9.  Transgene-mediated enkephalin expression attenuates signs of naloxone-precipitated morphine withdrawal in rats with neuropathic pain.

Authors:  Shuanglin Hao; Jian Hu; David J Fink
Journal:  Behav Brain Res       Date:  2008-08-12       Impact factor: 3.332

10.  Therapeutic manipulation of peroxynitrite attenuates the development of opiate-induced antinociceptive tolerance in mice.

Authors:  Carolina Muscoli; Salvatore Cuzzocrea; Michael M Ndengele; Vincenzo Mollace; Frank Porreca; Francesca Fabrizi; Emanuela Esposito; Emanuela Masini; George M Matuschak; Daniela Salvemini
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.